KZR - NASDAQ
Kezar Life Sciences, Inc.
$7.29
+0.0000%Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
At a Glance
Live Snapshotkzr
Shares Outstanding
Last Annual Value
7.32M
3-Year CAGR
-52%
5-Year CAGR
-30%
10-Year CAGR
-6%
Kezar Life Sciences, Inc. Competitors Analysis of shares-outstanding
| Company | shares-outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Kezar Life Sciences, Inc. NASDAQ:KZR | 7.32M | -53.5% | -32.6% | -5.6% | |
 OnKure Therapeutics, Inc. NASDAQ:OKUR | 13.52M | 0.4% | 49.4% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 30.07M | 4.2% | 7.9% | 34.0% | |
 Xilio Therapeutics, Inc. NASDAQ:XLO | 83.59M | 249.1% | 191.0% | N/A | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 4.90M | 1.8% | 11.7% | 21.5% | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 46.38M | 14.4% | 12.6% | 41.5% | |
 X4 Pharmaceuticals, Inc. NASDAQ:XFOR | 42.29M | 92.5% | 118.0% | 124.1% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 9.88M | -26.5% | -24.3% | N/A |
Kezar Life Sciences, Inc. Fair Value Envelope
Related Guides
Continue your KZR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.